| Loubna N Hatem, DO | |
|
201 Park St, Bowling Green, KY 42101-1708 | |
| (270) 781-5111 | |
| Not Available |
| Full Name | Loubna N Hatem |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 7 Years |
| Location | 201 Park St, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326576661 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Medical Center (bowling Green) | Bowling green, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gilbert Barbee Moore And Mcilvoy Psc | 4082511167 | 223 |
News Archive
Recent study published in the International Journal of Surgery investigates tested applicability of Google Glass in daily pediatric surgical practice
About 200 million people across 75 of the poorest countries in the world are now infected by the blood parasite Schistosoma haematobium (S. haematobium). The infection causes severe urogenital disease, but also causes bladder cancer in a number of patients and why this occurs is not clear.
Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.
On 8 November, the World Health Organization (WHO) announced a shortfall of artemether + lumefantrine, an artemisinin-based combination therapy (ACT) used to treat malaria, for the period between November 2004 and March 2005
› Verified 1 days ago
| Entity Name | Gilbert Barbee Moore & Mcilvoy Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114948288 PECOS PAC ID: 4082511167 Enrollment ID: O20031217000136 |
News Archive
Recent study published in the International Journal of Surgery investigates tested applicability of Google Glass in daily pediatric surgical practice
About 200 million people across 75 of the poorest countries in the world are now infected by the blood parasite Schistosoma haematobium (S. haematobium). The infection causes severe urogenital disease, but also causes bladder cancer in a number of patients and why this occurs is not clear.
Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.
On 8 November, the World Health Organization (WHO) announced a shortfall of artemether + lumefantrine, an artemisinin-based combination therapy (ACT) used to treat malaria, for the period between November 2004 and March 2005
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Loubna N Hatem, DO 201 Park St, Bowling Green, KY 42101-1708 Ph: (270) 783-0451 | Loubna N Hatem, DO 201 Park St, Bowling Green, KY 42101-1708 Ph: (270) 781-5111 |
News Archive
Recent study published in the International Journal of Surgery investigates tested applicability of Google Glass in daily pediatric surgical practice
About 200 million people across 75 of the poorest countries in the world are now infected by the blood parasite Schistosoma haematobium (S. haematobium). The infection causes severe urogenital disease, but also causes bladder cancer in a number of patients and why this occurs is not clear.
Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.
On 8 November, the World Health Organization (WHO) announced a shortfall of artemether + lumefantrine, an artemisinin-based combination therapy (ACT) used to treat malaria, for the period between November 2004 and March 2005
› Verified 1 days ago
Dr. Parisa Samimi, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-783-0452 Fax: 270-780-0466 | |
Dr. Benjamin Aaron Banasiewicz, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 523 Park St, Bowling Green, KY 42101 Phone: 270-781-0075 Fax: 270-796-2250 | |
Jeffery W. Nemec, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 350 Park St, Suite 203, Bowling Green, KY 42101 Phone: 270-781-0075 Fax: 270-781-0143 | |
Dr. Shebna Unes Kunju, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 523 Park St, Bowling Green, KY 42101 Phone: 270-781-0075 Fax: 270-796-2250 | |
Devin G. Trevor, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 350 Park St, Suite 203, Bowling Green, KY 42101 Phone: 270-781-0075 Fax: 270-781-0143 | |
Dr. Sara L. Mangold, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-781-5111 Fax: 270-780-0498 | |
Angela D. Yates, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-780-0562 Fax: 270-780-0466 |